Usefulness of the NMP22BladderChek test for screening and follow-up of bladder cancer

Korean Journal of Urology

Volumn 51, Issue 2, 2010, Pages 88-93

  Choi, Hwa Sub ^a   Lee, Sang Ik ^a   Kim, Dong Jun ^a   Jeong, Tae Yoong ^a  

^a Catholic Kwandong University   (South Korea)

Author keywords

Cytology; Nuclear matrix protein 22; Urinary bladder neoplasms

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; CANCER GRADING; CANCER INVASION; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MATRIX PROTEIN 22 BLADDER CHECK TEST; PYURIA; SENSITIVITY AND SPECIFICITY; URINE CYTOLOGY;

EID: 77149139120     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2010.51.2.88     Document Type: Article

References (18)

1. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083-6.
2. Park JO, Moon DG, Cheon J, Kim JJ, Yoon DK. Urinary NMP (nuclear matrix protein) 22 in screening and post-treatment follow-up bladder cancer. Korean J Urol 1999;40:551-6.
3. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP 3rd, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 2005;66(6 Suppl 1):35-63.
4. Bassi P, De Marco V, De Lisa A, Mancini M, Pinto F, Bertoloni R, et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature. Urol Int 2005;75:193-200.
5. Quek ML, Sanderson K, Daneshmand S, Stein JP. New molecular markers for bladder cnacer detection. Curr Opin Urol 2004;14:259-64.
6. Miyanaga N, Akaza H, Ishikawa S, Ohtani M, Noguchi R, Kawai K, et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997;31:163-8.
7. Murphy WM, Emerson LD, Chandler RW, Moinuddin SM, Soloway MS. Flow cytometry versus urinary cytology in the evaluation of patients with bladder cancer. J Urol 1986;136:815-9.
8. Murphy WM, Soloway MS, Jukkola AF, Crabtree WN, Ford KS. Urinary cytology and bladder cancer. The cellular features of transitional cell neoplasms. Cancer 1984;53:1555-65.
9. Kwon DH, Hong SJ. The clinical utility of BTA TRAK, BTA stat, NMP22 and urine cytology in the diagnosis of bladder cancer: a comparative study. Korean J Urol 2003;44:721-6.
10. Landman J, Chang Y, Kavaler E, Droller MJ, Liu BC. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer. Urology 1998;52:398-402.
11. Glas AS, Roos D, Deutekom M, Zwinderman AH, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. J Urol 2003;169:1975-82.
12. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810-6.
13. Tomera KM. NMP22BladderChek test: point-of-care technology with life-and money-saving potential. Expert Rev Mol Diagn 2004;4:783-94.
14. Atsü N, Ekici S, Oge O, Ergen A, Hascelik G, Ozen H. False-positive result of the NMP22 test due to hematuria. J Urol 2002;167:555-8.
15. Chang SH, Kim YH, Kim ME. Urinary survivin test compared to the nuclear matrix protein (NMP)-22 test and urine cytology for the diagnosis of bladder cancer. Korean J Urol 2006;47:1041-5.
16. Kim H, Chang SG, Kim JI. Significance of urinary NMP22 in patients with bladder tumor as a diagnostic test. Korean J Urol 1998;39:450-3.
17. Sharma S, Zippe CD, Pandrangi L, Nelson D, Agarwal A. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat. J Urol 1999;162:53-7.
18. Ozer G, Altinel M, Kocak B, Yazicioglu A, Gonenc F. Value of urinary NMP-22 in patients with renal cell carcinoma. Urology 2002;60:593-7.